Description

Larazotide acetate is a peptide which is an orally active zonulin antagonist. Larazotide acetate shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide acetate can be used for the research of celiac disease and infection.–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–COVID-19-immunoregulation–C34H59N9O12—-[1]Di Micco S, et al. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. Int J Mol Sci. 2021 Aug 30;22(17):9427.|[2]Gopalakrishnan S, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012 May;35(1):86-94.–881851-50-9–785.89–99.74–O=C([C@H](C(C)C)NC([C@H](CC(C)C)NC([C@H](C(C)C)NC(CNC(CN)=O)=O)=O)=O)N[C@@H](CCC(N)=O)C(N1[C@@H](CCC1)C(NCC(O)=O)=O)=O.CC(O)=O–Inflammation/Immunology–DMSO : 3.2 mg/mL (ultrasonic;warming)|H2O : 16.67 mg/mL (ultrasonic)–Gap Junction Protein—-Cytoskeleton–Peptides